Company / Current Assets
BridgeBio Pharma, Inc. Current Assets History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$797.7M
FY2025
5-year range
$477.6M / $888.9M
FY2021-FY2025
Trend
+10.7%
vs FY2024
Sector context
#71 of 213
Health Care
What the data says
At $798M, BridgeBio Pharma, Inc.'s current assets ranks #71 of 213 in the Health Care sector. Improved from $478M to $798M over the past 2 years.
Based on SEC 10-K filings.
$798M in FY2025 with a 5-year CAGR of +4.4%.
Improved from $478M to $798M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +13.3%
- 5-Year CAGR
- +4.4%
- 10-Year CAGR
- -
Sector benchmark
#71 of 213 in Health CareTop 33% of 213This company $797.7M Sector average $2.5B
▼
-68.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.4%, indicating consistent growth.
- In FY2025, current assets increased 10.7% year-over-year.
- Ranks #71 out of 213 companies in the Health Care sector.
- Peak current assets was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $797.7M | +10.7% |
| FY2024 | $720.7M | +50.9% |
| FY2023 | $477.6M | -13.0% |
| FY2022 | $548.9M | -38.3% |
| FY2021 | $888.9M | +38.3% |
| FY2020 | $642.8M | +13.0% |
| FY2019 | $568.6M | +27.7% |
| FY2018 | $445.2M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026